Clinical trials
Fibrosis clinical trials
Below are recruiting fibrosis clinical trials, each written for real people, not researchers. We’re tracking 437 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06940531Recruiting
Tracking causes of lung flare-ups in cystic fibrosis
This study aims to understand what causes and increases the risk of lung infections (exacerbations) in people with cystic fibrosis. It involves regular monitoring and sample collection at home and in the clinic to identify early warning signs.
Manchester, ManchesterAges 5 years+ - NCT07223255Recruiting
Mediterranean diet study for children with cystic fibrosis
This study tests whether a Mediterranean-style diet can improve gastrointestinal health in children with cystic fibrosis. It requires families to follow the diet for 6 months and attend regular clinic visits.
Lebanon, New HampshireAges 3–18 - NCT07299695RecruitingPhase 3
IVIG for sudden worsening of IPF
This trial tests whether giving a medication called intravenous immunoglobulin (IVIG) can help people with IPF who are hospitalized for a sudden worsening of their lung condition. The treatment aims to reduce inflammation and improve recovery.
PátraiAges 18 years+ - NCT07484607Recruiting
Study on infections and treatments in cystic fibrosis exacerbations
This study looks at how lung infections and inflammation affect people with cystic fibrosis during severe flare-ups. It aims to understand which antibiotics work best and why, so your care team can choose the right treatment for you.
CardiffAges 16 years+ - NCT06845345Enrolling by invitationPhase 4
Can a special diet or pills help liver health?
This study compares two treatments for liver scarring in people with overweight or related health issues. One group follows a special diet with restricted eating times, while the other takes a combination of two medications (naltrexone and bupropion). It aims to see which approach better improves liver fibrosis.
RotterdamAges 18–75 - NCT06968845RecruitingPhase 2
Study of LTI-03 for Idiopathic Pulmonary Fibrosis
This trial tests an inhaled drug called LTI-03 to see if it can help people with idiopathic pulmonary fibrosis (IPF). It may be an option for those with moderate lung function who are stable on their current treatment.
Birmingham, AlabamaAges 40 years+ - NCT07761377Recruiting
Using AI to spot lung scarring on CT scans
This study tests whether an AI tool can correctly find lung scarring (pulmonary fibrosis) on CT scans as well as doctors do. The results could lead to faster, more consistent detection of this condition.
TaichungAges 20 years+ - NCT01915511Recruiting
Long-term registry for new or worsening lung scarring
This study collects health information over time from people with newly diagnosed idiopathic pulmonary fibrosis (IPF) or other lung scarring diseases that are getting worse. It’s meant to better understand disease patterns and outcomes, which may help doctors plan future care.
Birmingham, AlabamaAges 21 years+ - NCT07720375RecruitingPhase 2
Study of a new medication for adults with bronchiectasis
This study tests a new medication called Galvokimig to see if it helps reduce lung infections and improve quality of life in adults with bronchiectasis (a condition where lung airways are damaged and fill with mucus). It is a 24 to 52 week treatment, and you will be monitored closely for safety and effectiveness.
Plantation, FloridaAges 18–80 - NCT07750535Recruiting
Liver fat and scarring in wheat-sensitive patients
This study looks at whether people with non-celiac wheat sensitivity or other digestive conditions have more fat in their liver or liver scarring. It aims to understand if wheat-related issues are linked to liver health.
Palermo, PalermoAges 18–65 - NCT06967805RecruitingPhase 2
Study of MTX-463 for Idiopathic Pulmonary Fibrosis
This trial tests an experimental drug called MTX-463 for people with idiopathic pulmonary fibrosis (IPF). It aims to see if targeting a protein called WISP1 can slow lung scarring and help you breathe better.
Birmingham, AlabamaAges 40 years+ - NCT06632444RecruitingPhase 3
Study of survodutide for liver disease NASH/MASH with fibrosis
This trial tests an investigational drug called survodutide for people with NASH or MASH, a type of fatty liver disease that also has liver scarring (moderate or advanced fibrosis). The goal is to see if the drug can improve the condition.
Birmingham, AlabamaAges 18 years+ - NCT07284459RecruitingPhase 2
Testing PIPE 791 for idiopathic pulmonary fibrosis
This trial tests an investigational drug called PIPE 791 for people with idiopathic pulmonary fibrosis (IPF). It aims to see if the drug slows lung function decline, and you may continue your current IPF medicine.
Rosario, Santa Fe ProvinceAges 40 years+ - NCT06951217RecruitingPhase 2
Long-term safety study of an inhaled drug for lung scarring
This study continues treatment for people who already completed a previous study with an Avalyn inhaled antifibrotic drug. It aims to check the long-term safety of the medication for patients with certain types of lung scarring.
Birmingham, AlabamaAges 18 years+ - NCT07201922RecruitingPhase 3
Can a new pill help slow lung changes in people with family risk?
This trial tests a new drug called nerandomilast to see if it can slow down early lung changes in people who have a close family member with a type of lung scarring called pulmonary fibrosis. You may join if you are 40 or older, have a parent, sibling, or child with this condition, and have early signs of lung changes on a CT scan.
Los Angeles, CaliforniaAges 40 years+ - NCT06210555Recruiting
MRI Study of Kidney Donors, Recipients, and Healthy People
This study uses advanced MRI scans to look at kidney health in living donors, transplant recipients, and healthy people. It aims to find links between MRI results and kidney function, fibrosis (scarring), and aging.
Aarhus, Central JutlandAges 18–80 - NCT05428826RecruitingPhase 4
Stopping steroids early if PET/CT looks negative
This study tests whether some people with idiopathic retroperitoneal fibrosis can stop prednisone earlier when a PET/CT scan shows no concerning activity. It may reduce steroid side effects while keeping the disease under control.
Agen, FranceAges 18 years+ - NCT06660992RecruitingPhase 3
Study of HSK31858 for non-CF bronchiectasis
This trial tests a new medicine, HSK31858, for people with non-cystic fibrosis bronchiectasis (a lung condition causing chronic cough and infections). It aims to see if the drug reduces lung flare-ups and improves symptoms.
Guangzhou, GuangdongAges 18 years+ - NCT06487273Recruiting
SIMEOX device for mucus clearance at home in bronchiectasis
This study tests a home-use device called SIMEOX, which helps clear mucus from your lungs. It is for adults with bronchiectasis (not cystic fibrosis) who have frequent lung infections.
AbbevilleAges 18 years+ - NCT05674994RecruitingPhase 3
Steroid versus placebo for sudden worsening of lung scarring
This Phase 3 trial studies whether glucocorticoid (steroid) medicine helps people with idiopathic pulmonary fibrosis (IPF) who have a sudden flare-up, compared with an inactive placebo. You may be helped if steroids improve breathing and recovery during these acute episodes, but the study is designed to test that clearly.
AngersAges 18 years+ - NCT07709494RecruitingPhase 1
Inhaled Rev-56 for healthy volunteers and people with bronchiectasis
This trial tests an inhaled drug called Rev-56 in healthy adults and in adults with non-cystic fibrosis bronchiectasis who have a chronic lung infection with Pseudomonas aeruginosa. It aims to see if the drug is safe, well-tolerated, and helps reduce the bacteria in the lungs.
Miami, FloridaAges 18–80 - NCT07683728Recruiting
Observational study of progressive pulmonary fibrosis (PPF) in China
This study is a registry that collects information from people in China who have progressive pulmonary fibrosis (PPF), a lung condition that gets worse over time. It aims to better understand the disease and help doctors improve care.
BeijingAges Any age - NCT07048262RecruitingPhase 2
Study of an inhaled drug for adults with non-CF bronchiectasis
This trial tests an inhaled medication called CSL787 to see if it can help people with non-cystic fibrosis bronchiectasis (a lung condition that causes frequent infections and breathing problems). The study looks at different doses and checks how well the drug works and if it is safe.
QueenslandAges 18–85 - NCT04047576RecruitingPhase 2/Phase 3
Sirolimus for unknown-cause retroperitoneal scarring
This trial tests sirolimus to treat idiopathic (unknown-cause) retroperitoneal fibrosis, a condition where scar tissue forms in the belly behind the kidneys. You may be considered if imaging and blood tests suggest active inflammation, and if you’re able to safely take the study medicine and return for follow-up.
Beijing, Beijing MunicipalityAges 18 years+
Hear when a new Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for fibrosis?
- Yes. Clin2 currently lists 437 recruiting fibrosis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a fibrosis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a fibrosis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.